Nicoletta Urbano

Summary

Country: Italy

Publications

  1. ncbi A proposal for phosphor imager acceptance testing procedure and routine quality controls in nuclear pharmacy practice
    Nicoletta Urbano
    Department of Nuclear Medicine, University Hospital Ospedali Riuniti, Foggia, Italy
    Nucl Med Commun 32:611-6. 2011
  2. ncbi Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control
    Nicoletta Urbano
    Department of Nuclear Medicine, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture PZ, Italy
    Nucl Med Commun 28:943-50. 2007
  3. ncbi Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine
    Sergio Modoni
    Department of Nuclear Medicine, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture PZ, Italy
    Cancer Biother Radiopharm 22:289-95. 2007
  4. ncbi Radioiodine treatment of Plummer and multinodular toxic and nontoxic goiter disease by the first approximation dosimetry method
    Matteo Zingrillo
    Department of Endocrinology, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
    Cancer Biother Radiopharm 22:256-60. 2007
  5. ncbi Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT)
    Nicoletta Urbano
    Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Eur J Nucl Med Mol Imaging 34:68-77. 2007

Collaborators

Detail Information

Publications5

  1. ncbi A proposal for phosphor imager acceptance testing procedure and routine quality controls in nuclear pharmacy practice
    Nicoletta Urbano
    Department of Nuclear Medicine, University Hospital Ospedali Riuniti, Foggia, Italy
    Nucl Med Commun 32:611-6. 2011
    ..The aim of this study was to define a set of tests for setting up a specific acceptance testing procedure and routine quality controls for this instrument...
  2. ncbi Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control
    Nicoletta Urbano
    Department of Nuclear Medicine, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture PZ, Italy
    Nucl Med Commun 28:943-50. 2007
    ..The radioimmunoconjugate may be administered to the patient only if the radiolabelling yield is higher than 95%...
  3. ncbi Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine
    Sergio Modoni
    Department of Nuclear Medicine, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture PZ, Italy
    Cancer Biother Radiopharm 22:289-95. 2007
    ..This first in vivo molecular and morphologic evidence of cell differentiation in human cancer and low toxicity of nevirapine strongly encourage its use in dedifferentiated thyroid cancer treatment...
  4. ncbi Radioiodine treatment of Plummer and multinodular toxic and nontoxic goiter disease by the first approximation dosimetry method
    Matteo Zingrillo
    Department of Endocrinology, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
    Cancer Biother Radiopharm 22:256-60. 2007
    ....
  5. ncbi Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT)
    Nicoletta Urbano
    Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Eur J Nucl Med Mol Imaging 34:68-77. 2007
    ..A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT) application. Preclinical and clinical results are described...